Epidemiology of lung cancer prognosis: quantity and quality of life.
Epidemiology of lung cancer prognosis: quantity and quality of life.
复制标题
DOI：
10.1007/978-1-59745-416-2_24
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Yang, Ping
中科院分区：
文献类型：
--
作者：
Yang, Ping
原发性肺癌的临床表现、组织病理学和治疗反应具有很大的异质性；与其他疾病一样，预后由两个重要方面组成：生存和生活质量 (QOL)。肺癌的生存率主要取决于疾病分期和治疗方式，五年生存率在三十年来一直保持在 15% 的稳定水平。生活质量关注受健康状况和医疗干预影响的生活方面；身体机能与治疗副作用之间的平衡长期以来一直是护理人员和患者关注的问题。显然需要易于测量的生物标志物在治疗前对患者进行分层，以获得最佳的生存和生活质量结果，并监测治疗反应和毒性。针对肿瘤发生、生长和转移机制的靶向治疗前景广阔，并积极转化为临床实践。长期肺癌 (LTLC) 幸存者是指诊断后仍存活五年的人。关于 LTLC 幸存者的健康和生活质量的知识有限，因为肺癌的结果研究主要集中在短期生存。肺癌治疗、衰老、吸烟和饮酒、合并症和心理社会因素的独立或综合影响可能会导致肺癌幸存者的后期影响，包括器官功能障碍、慢性疲劳、疼痛或过早死亡。获得的新知识应该可以帮助肺癌幸存者、他们的医疗保健提供者和他们的护理人员，为建立临床建议提供证据，以提高他们的长期生存和健康相关的生活质量。
Primary lung cancer is very heterogeneous in its clinical presentation, histopathology, and treatment response; and like other diseases, the prognosis consists of two essential facets: survival and quality of life (QOL). Lung cancer survival is mostly determined by disease stage and treatment modality, and the five-year survival rate has been in a plateau of 15% for three decades. QOL is focused on life aspects that are affected by health conditions and medical interventions; the balance of physical functioning and suffering from treatment side effects has long been a concern of care providers as well as patients. Obviously needed are easily-measurable biologic markers to stratify patients prior to treatment for optimal results in survival and QOL and to monitor treatment responses and toxicities. Targeted therapies towards the mechanisms of tumor development, growth, and metastasis are promising and actively translated into clinical practice. Long-term lung cancer (LTLC) survivors are people who are alive five years after the diagnosis. Knowledge about the health and QOL in LTLC survivors is limited because outcome research in lung cancer has been focused mainly on short-term survival. The independent or combined effects of lung cancer treatment, aging, smoking and drinking, comorbid conditions, and psychosocial factors likely cause late effects including organ malfunction, chronic fatigue, pain, or premature death among lung cancer survivors. New knowledge to be gained should help lung cancer survivors, their healthcare providers, and their caregivers by providing evidence for establishing clinical recommendations to enhance their long-term survival and health-related QOL.